GFL Environmental Inc. Subordinate voting shares no par value vs Kymera Therapeutics Inc. Common Stock — how do they compare? GFL Environmental Inc. Subordinate voting shares no par value trades at $42.95 (market cap $18.74B), while Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B). The key difference: GFL Environmental Inc. Subordinate voting shares no par value is far larger — about 2.1× Kymera Therapeutics Inc. Common Stock's market cap, and GFL Environmental Inc. Subordinate voting shares no par value pays a 0.16% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GFL Environmental Inc. Subordinate voting shares no par value for 6 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| GFL | KYMR | |
|---|---|---|
Market Cap | $18.74B | $8.88B |
Volume | 3,882,806 | 1,028,790 |
Sector | Industrials | Health |
52-Week High | $46.51 | $127.31 |
52-Week Low | $33.54 | $55.80 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $25.73B | $8.27B |
Dividend Yield | 0.16% | — |
Signals from Pluang's Aura AI — not financial advice
GFL trades at $42.75, up 0.87% today, with a bullish technical signal from moving averages. Recent Q2 2026 earnings missed estimates, but the company raised full-year 2026 guidance. Revenue is projected to grow to $7.0B in 2026, though net income is expected to turn negative. The company recently acquired SECURE Waste Infrastructure and announced a quarterly dividend, signaling financial activity.
Outlook is mixed: strong analyst buy consensus (77.8%) and positive news flow support upside, but negative profit margins and high valuation ratios pose risks. The stock's performance hinges on execution of growth initiatives and margin improvement in a competitive industrial sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
GFL Environmental provides environmental services across Canada and the United States. Its operations include solid waste management and other waste and environmental solutions.
Read more on GFL →Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →